This article is more than 5 years old. Information may no longer be current.
Baricitinib showed greater RA improvement in patient-reported outcomes vs adalimumab
Click Here to Manage Email Alerts
Among patients with rheumatoid arthritis, those who took baricitinib experienced greater improvement in patient-reported outcomes compared with patients who took adalimumab, according to a recently published study.
“These improvements tended to occur within the first weeks of treatment and were maintained throughout the 52-week trial,” the researchers wrote.
Investigators performed a double-blind phase 3 trial of 488 patients who took placebo, 487 patients who took 4-mg once-daily baricitinib and 330 who took 40-mg biweekly adalimumab along with methotrexate. The primary endpoint was improvement at 12 weeks.
Researchers found baricitinib had improvements in health assessment questionnaire-disability index, patient global assessment of disease activity, pain, functional assessment of chronic illness therapy-fatigue, SF-36 physical component score, EuroQol 5-D index scores and work productivity and activity impairment questionnaire-rheumatoid arthritis daily activity at 12 weeks. Improvements were maintained through 52 weeks. In addition, there were improvements in morning joint stiffness duration and severity, worst tiredness and worst joint pain. – by Will Offit
Disclosures: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts